Gene Therapy Marks a Turning Point for Rare Skin Diseases

image via New Scientist

September 5, 2025, 3:15 PM

• •B-VEC, the first gene therapy for a non-cancerous skin disorder, and pz-cel, offer new hope and improved quality of life.
• •These therapies are shifting the focus from symptom management to molecular repair, especially for conditions like epidermolysis bullosa.
• •Research continues to explore topical, graft-based, and stem-cell therapies to expand treatment options.
• •Future developments in genome-editing technologies may provide more targeted and precise genetic correction.

Gene therapy has emerged as a groundbreaking treatment for rare skin diseases, shifting the focus from symptom management to molecular repair. The approval of treatments like beremagene geperpavec (B-VEC) and prademagene zamikeracel (pz-cel) has led to significant improvements in wound healing and quality of life for individuals affected by conditions like epidermolysis bullosa. These therapies, while not cures, offer a meaningful step forward, providing families with hope and the potential for a future with reduced pain and increased independence. Ongoing research explores expanding these treatments to other inherited skin disorders and developing more advanced methods, such as genome-editing and stem-cell based therapies, to enhance precision and durability.

Read original article